HAVRIX
Genel Bilgiler
- Ticaret Unvanı:
- HAVRIX PED. 720 MCG 1 ENJEKTOR
- Aktif bileşen:
- Hepatit a, inaktif, tüm virüs
- Mevcut itibaren:
- GLAXO SMITHKLINE
- ATC kodu:
- J07BC02
- INN (International Adı):
- hepatitis a, inactivated, whole virus
- Reçete türü:
- Normal
- İçin kullanmak:
- İnsanlar
- İlaç türü:
- allopatik ilaç
Belgeler
- genel halk için:
- Bu ürün için bilgi broşürü şu anda mevcut değil, bizim müşteri hizmetleri bir istek gönderebilir ve bunu elde edebiliyoruz en kısa sürede biz size bildireceğiz.
Genel halk için bilgi broşürü isteyin.
- sağlık profesyonelleri için:
- Bu ürün için bilgi broşürü şu anda mevcut değil, bizim müşteri hizmetleri bir istek gönderebilir ve bunu elde edebiliyoruz en kısa sürede biz size bildireceğiz.
Sağlık profesyonelleri için bilgi broşürü isteyin.
Yerelleştirme
- Bulunduğu ülkeler::
-
Türkiye
- Dil:
- Türkçe
Terapötik bilgiler
- Terapötik alanı:
- Hepatit a, inaktif, tüm virüs
Diğer bilgiler
Durum
- Kaynak:
- TİTCK - TÜRKİYE İLAÇ VE TIBBİ CİHAZ KURUMU - Türkiye
- Yetkilendirme durumu:
- Aktif
- Yetkilendirme numarası:
- 8699522967322
- Yetkilendirme tarihi:
- 29-01-2013
- Son Güncelleme:
- 23-05-2018
- Bu ürün için bilgi broşürü şu anda mevcut değil, bizim müşteri hizmetleri bir istek gönderebilir ve bunu elde edebiliyoruz en kısa sürede biz size bildireceğiz.
Genel halk için bilgi broşürü isteyin.
- Bu belgeye erişim yalnızca kayıtlı kullanıcılar tarafından yapılabilir.
Tam erişim için şimdi kaydolun
28-11-2018
Minister Bruno Bruins bereikt akkoord over openbare verlaging van prijzen voor geneesmiddelen tegen hepatitis C
Minister Bruno Bruins voor Medische Zorg heeft besloten acht nieuwe medicijnen tegen chronische hepatitis C te blijven vergoeden. Tot nu toe golden vertrouwelijke prijsafspraken voor deze middelen, maar die zijn vanaf 1 januari 2019 niet meer nodig. Twee leveranciers hebben gehoor gegeven aan een oproep van de minister voor een openbare prijsverlaging.
Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport
14-9-2018
Pending EC decision: Respiporc FLUpan H1N1, inactivated influenza A virus/human strain: A/Jena/VI5258/2009(H1N1)pdm09, Opinion date: 13-Sep-2018
Europe - EMA - European Medicines Agency
14-9-2018
Pending EC decision: Versican Plus DHPPi/L4R, canine distemper, canine adenovirus, canine parvovirosis, canine parainfluenza virus (live attenuated), canine leptospirosis and rabies (inactivated) vaccine, Opinion date: 13-Sep-2018
Europe - EMA - European Medicines Agency
14-9-2018
Pending EC decision: Versican Plus DHPPi/L4, canine distemper, canine adenovirus, canine parvovirosis, canine parainfluenza virus (live attenuated) and canine leptospirosis (inactivated) vaccine, Opinion date: 13-Sep-2018
Europe - EMA - European Medicines Agency
14-9-2018
Pending EC decision: Versican Plus Pi/L4, Canine parainfluenza virus (live attenuated) and canine leptospirosis (inactivated) vaccine, Opinion date: 13-Sep-2018
Europe - EMA - European Medicines Agency
14-9-2018
Pending EC decision: Versican Plus Pi/L4R, Canine parainfluenza virus (live attenuated), canine leptospirosis and rabies (inactivated) vaccine, Opinion date: 13-Sep-2018
Europe - EMA - European Medicines Agency
4-9-2018
Veterinary medicine European public assessment report (EPAR): Gripovac 3, inactivated influenza-A virus / swine, Revision: 1, Withdrawn
Europe - EMA - European Medicines Agency
4-9-2018
Veterinary medicine European public assessment report (EPAR): Porcilis PCV M Hyo, porcine circovirus (inactivated) and porcine enzootic pneumonia vaccine, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
26-7-2018
Veterinary medicine European public assessment report (EPAR): Bovilis Blue-8, bluetongue virus vaccine, serotype 8 (inactivated), Revision: 1, Authorised
Europe - EMA - European Medicines Agency
29-6-2018
Nieuwe behandeling tegen hepatitis C in het basispakket
Een nieuwe behandeling tegen chronische hepatitis C met het geneesmiddel Vosevi wordt vanaf 1 juli 2018 vergoed vanuit het basispakket. Dat heeft minister Bruno Bruins (Medische Zorg) besloten nadat hij met de fabrikant onderhandeld heeft over de prijs van het nieuwe middel. Vosevi kan worden ingezet bij alle patiënten met een chronische hepatitis C infectie. Met de opname van Vosevi zijn nu alle geneesmiddelen voor hepatitis C patiënten in Nederland beschikbaar vanuit het basispakket .
Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport
15-6-2018
Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Revision: 5, Authorised
Europe - EMA - European Medicines Agency
12-6-2018
Human medicines European public assessment report (EPAR): Zutectra, human hepatitis-B immunoglobulin, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
30-5-2018
Procleix West Nile Virus (WNV) Assay
Product approval information is indicated for the qualitative detection of West Nile Virus (WNV) RNA in plasma specimens from individual human donors, including volunteer donors of whole blood and blood components, and other living donors.
FDA - U.S. Food and Drug Administration
29-5-2018
Human medicines European public assessment report (EPAR): Infanrix Hexa, diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate va
Europe - EMA - European Medicines Agency
28-5-2018
Pending EC decision: Porcilis PCV M Hyo, porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated), Opinion date: 25-May-2018
Europe - EMA - European Medicines Agency
22-5-2018
Human medicines European public assessment report (EPAR): Hexyon, diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (
Europe - EMA - European Medicines Agency
27-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): Purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain), decision type: , therapeutic area: , PIP number: P/0219/2018
Opinion/decision on a Paediatric investigation plan (PIP): Purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain), decision type: , therapeutic area: , PIP number: P/0219/2018
Europe - EMA - European Medicines Agency
27-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain / split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain / split i
Opinion/decision on a Paediatric investigation plan (PIP): Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain / split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain / split influenza virus, inactivated containing antigens equivalent to the B-like strain, decision type: , therapeutic area: , PIP number: P/0155/2018
Europe - EMA - European Medicines Agency
13-9-2018
European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018
This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...
Europe - EMA - European Medicines Agency
22-8-2018
BTVPUR (Merial)
BTVPUR (Active substance: Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 4)) - Centralised - 2-Monthly update - Commission Decision (2018)5630 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2231/II/10
Europe -DG Health and Food Safety
4-7-2018
ERYSENG PARVO (Laboratorios Hipra, S.A.)
ERYSENG PARVO (Active substance: Inactivated porcine parvovirus, strain NADL-2 / Inactivated Erysipelothrix rhusiopathiae, strain R32E11) - Centralised - Yearly update - Commission Decision (2018) 4354 of Wed, 04 Jul 2018
Europe -DG Health and Food Safety
29-6-2018
Porcilis PCV M Hyo (Intervet International B.V.)
Porcilis PCV M Hyo (Active substance: Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)4166 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3796/II/7
Europe -DG Health and Food Safety
19-6-2018
Aftovaxpur Doe (Merial)
Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Renewal - Commission Decision (2018)3891 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2292/R/8
Europe -DG Health and Food Safety
20-4-2018
Veterinary medicine European public assessment report (EPAR): Suvaxyn Circo, porcine circovirus vaccine (inactivated, recombinant), Revision: 0, Authorised
Europe - EMA - European Medicines Agency
9-2-2018
Suvaxyn Circo (Zoetis Belgium S.A.)
Suvaxyn Circo (Active substance: Porcine circovirus vaccine (inactivated, recombinant)) - New authorisation - Commission Decision (2018)861 of Fri, 09 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4242
Europe -DG Health and Food Safety